Sam Moskowitz, MD
Gastroenterology · Brooklyn, NYNPI 1851377394
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $269,726 of the $332,142 with a category attached, or 81.2%. 36 manufacturers reported payments, led by AbbVie at 38.7% of the total. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,374 payments — averaging $241.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$128K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$57K
- Pfizer$32K
- Gilead$32K
- Johnson & Johnson$31K
- Lilly USA, LLC$27K
- plus $25K from 30 others
What the payments were for
- Consulting fees$9,5503%
- Speaking & faculty fees$269,72681%
- Travel & lodging$27,1028%
- Food & beverage$25,6348%
- Education$1300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 300 | $128,388 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 424 | $57,018 |
| Pfizer | 82 | $32,236 |
| Gilead | 79 | $31,797 |
| Johnson & Johnson | 78 | $30,923 |
| Lilly USA, LLC | 38 | $26,786 |
| Phathom Pharmaceuticals, Inc. | 28 | $8,973 |
| Eli Lilly | 8 | $5,900 |
| Redhill Biopharma Inc. | 39 | $3,184 |
| Ardelyx, Inc. | 20 | $1,505 |
| Intuitive Surgical | 4 | $886 |
| Ironwood Pharmaceuticals, Inc | 43 | $768 |
| Takeda Pharmaceuticals U.S.A., Inc. | 72 | $688 |
| Bristol Myers Squibb | 75 | $681 |
| Madrigal Pharmaceuticals | 22 | $468 |
| E.r. Squibb & Sons, L.L.C. | 2 | $240 |
| Evoke Pharma, Inc. | 6 | $235 |
| Concordia Pharmaceuticals Inc. | 7 | $228 |
| Novo Nordisk | 6 | $213 |
| Regeneron Healthcare Solutions, Inc. | 6 | $182 |
| Intercept Pharmaceuticals, Inc. | 4 | $176 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Braintree Laboratories, Inc. | 7 | $121 |
| Merck | 4 | $76 |
| Ferring Pharmaceuticals Inc. | 4 | $56 |
| Intra-sana Laboratories | 1 | $50 |
| Romark Laboratories, LC | 4 | $45 |
| Celltrion USA Inc. | 2 | $38 |
| Boston Scientific | 1 | $34 |
| CSL Behring | 1 | $23 |
| GSK | 1 | $21 |
| Shionogi Inc | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$332,142 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 12 | $335,794 |
| CreonLipase/Protease/Amylase | 26 | $154,666 |
| Lactulose | 33 | $150,793 |
| IbsrelaTenapanor Hcl | 25 | $102,137 |
| LinzessLinaclotide | 67 | $80,209 |
| XifaxanRifaximin | 34 | $74,533 |
| RinvoqUpadacitinib | 12 | $72,160 |
| MounjaroTirzepatide | 55 | $55,045 |
| VoqueznaVonoprazan Fumarate | 46 | $44,483 |
| VemlidyTenofovir Alafenamide | 17 | $35,311 |
| OzempicSemaglutide | 27 | $32,308 |
| TrulancePlecanatide | 21 | $16,410 |
| Dexlansoprazole DrDexlansoprazole | 47 | $16,224 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 125 | $6,579 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 39 | $5,350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $30,923 | $335,79412 claims |
| AbbVieCreon, Linzess, Rinvoq | $128,388 | $307,036105 claims |
| Ardelyx, Inc.Ibsrela | $1,505 | $102,13725 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Plenvu | $57,018 | $96,29394 claims |
| Lilly USA, LLCMounjaro | $26,786 | $55,04555 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $8,973 | $44,48346 claims |
| GileadVemlidy | $31,797 | $35,31117 claims |
| Novo NordiskOzempic | $213 | $32,30827 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $56 | $1,89011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in Brooklyn
- Jianjun LiBrooklyn$211K
- Nison BadalovBrooklyn$200K
- Kevin TinBrooklyn$168K
- Jonathan ErberBrooklyn$164K
- Rabin RahmaniBrooklyn$155K
- Kayane Hanna-HindyBrooklyn$151K
- Kadirawelpillai IswaraBrooklyn$148K
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.